The power of compounding can build huge amounts of passive income.
These healthcare players offer you dividends and a strong earnings picture.
They both have pretty impressive pasts, and their prospects look just as bright.
These two dividend growth stocks are potent capital appreciation vehicles.
/Abbott%20Laboratories%20HQ%20photo-%20by%20Sundry%20Photography%20via%20iStock.jpg)
Despite Abbott’s recent underperformance over the past year, Wall Street analysts remain optimistic about the stock’s prospects.
/Abbott%20Laboratories%20vials%20and%20Logo-by%20Melniov%20Dmitriy%20via%20Shutterstock.jpg)
Abbott has underperformed the broader market over the past year, but Wall Street analysts are optimistic about the stock’s prospects.
Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat.
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:ABT),(NASDAQ:CELH),(NASDAQ:MNST),(NYSE:BRBR) EQNX::TICKER_END